A Phase 3 interventional study of aprepitant and Comparator: ondansetron in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 6th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 848 is above the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of chemotherapy may opt to participate in an optional second cycle during which the patient will receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant will be given in place of the oral formulation on study day one. Study drug administration on subsequent days will be given orally as in cycle 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
Drug: aprepitant · Drug: Comparator: ondansetron · Drug: Comparator: dexamethasone · Drug: Comparator; Placebo (unspecified)
Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
Drug: Comparator: ondansetron · Drug: Comparator: dexamethasone · Drug: Comparator: fosaprepitant dimeglumine · Drug: Comparator; Placebo (unspecified)
aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
Also known as: MK0869
Ondansetron 8 mg capsule Three day treatment period.
Also known as: Zofran®
dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
Also known as: DEXAMETHASONE TABLETS USP
fosaprepitant dimeglumine 115 mg
Also known as: EMEND®
dexamethasone 12mg Pbo tablets.
Aprepitant 80 mg \& 125 mg Pbo capsules.
Number of Patients Who Reported No Vomiting
The number of patients who reported No Vomiting in the overall phase in Cycle 1
Time frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
Number of Patients Who Reported Complete Response
The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.
Time frame: Overall phase (0-120 hours post initiation of MEC) in Cycle 1
This study was conducted at 58 investigative sites worldwide. The first patient entered the study on 16-Jan- 2007 and the last patient's last visit was on 28-Oct-2008.
| Milestone | Aprepitant Regimen | Standard Regimen |
|---|---|---|
| Started | 430 | 418 |
| Completed | 412 | 406 |
| Not completed | 18 | 12 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 4 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 |
The number of patients who reported No Vomiting in the overall phase in Cycle 1
| Participants | Aprepitant Regimen | Standard Regimen |
|---|---|---|
| Number of Patients Who Reported No Vomiting | 324 | 252 |
The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.
| Participants | Aprepitant Regimen | Standard Regimen |
|---|---|---|
| Number of Patients Who Reported Complete Response | 292 | 229 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aprepitant Regimen | — | 12/430 (2.8%) | 265/430 (61.6%) |
| Standard Regimen | — | 20/418 (4.8%) | 270/418 (64.6%) |
| Event | Aprepitant Regimen | Standard Regimen |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/430 | 3/418 |
| CellulitisInfections and infestations | 2/430 | 1/418 |
| NeutropeniaBlood and lymphatic system disorders | 1/430 | 1/418 |
| Abdominal PainGastrointestinal disorders | 0/430 | 1/418 |
| ConstipationGastrointestinal disorders | 0/430 | 1/418 |
| IleitisGastrointestinal disorders | 0/430 | 1/418 |
| General physical health deteriorationGeneral disorders | 0/430 | 1/418 |
| PyrexiaGeneral disorders | 0/430 | 1/418 |
| Abdominal InfectionInfections and infestations | 0/430 | 1/418 |
| Herpes ZosterInfections and infestations | 0/430 | 1/418 |
| Event | Aprepitant Regimen | Standard Regimen |
|---|---|---|
| ConstipationGastrointestinal disorders | 37/430 | 53/418 |
| HeadacheNervous system disorders | 42/430 | 49/418 |
| DiarrhoeaGastrointestinal disorders | 40/430 | 46/418 |
| FatigueGeneral disorders | 47/430 | 41/418 |
| AnorexiaMetabolism and nutrition disorders | 35/430 | 37/418 |
| AlopeciaSkin and subcutaneous tissue disorders | 28/430 | 32/418 |
| AstheniaGeneral disorders | 26/430 | 23/418 |
| NauseaGastrointestinal disorders | 18/430 | 11/418 |
| Abdominal PainGastrointestinal disorders | 17/430 | 16/418 |
| DyspepsiaGastrointestinal disorders | 14/430 | 13/418 |
| Age, Continuous(years) | Aprepitant Regimen | Standard Regimen | Total |
|---|---|---|---|
| Mean | 57.1 ± 11.8 | 55.9 ± 12.6 | 56.5 ± 12.2 |
| Sex: Female, Male(Participants) | Aprepitant Regimen | Standard Regimen | Total |
|---|---|---|---|
| Female | 327 | 325 | 652 |
| Male | 103 | 93 | 196 |
| Race/Ethnicity, Customized(participants) | Aprepitant Regimen | Standard Regimen | Total |
|---|---|---|---|
| Caucasian | 287 | 296 | 583 |
| Asian | 49 | 35 | 84 |
| Black | 26 | 20 | 46 |
| Multi-racial | 50 | 53 | 103 |
| Other | 18 | 14 | 32 |
| History of Motion Sickness(Participants) | Aprepitant Regimen | Standard Regimen | Total |
|---|---|---|---|
| Yes | 24 | 41 | 65 |
| No | 405 | 376 | 781 |
| No Data - Assessment Not Completed | 1 | 1 | 2 |
| History of Vomiting with Pregnancy(Participants) | Aprepitant Regimen | Standard Regimen | Total |
|---|---|---|---|
| Yes | 61 | 75 | 136 |
| No | 266 | 250 | 516 |
| Not Applicable- Male Patients | 103 | 93 | 196 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jan 2007 to primary completion in Oct 2008, 21 months.
Results were first posted in Nov 2009, 1 year after primary completion.
Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aprepitant · Fosaprepitant